Merck & Co Inc said on Monday it has applied for emergency use authorization in the US for its oral drug to treat mild-to-moderate patients of COVID-19.
The treatment, molnupiravir, has been developed with Ridgeback Biotherapeutics. If authorized, it would be the first oral antiviral medication.
Data released last week showed that molnupiravir could halve the chances of death or being hospitalized for those most at risk of contracting severe COVID-19.
Existing drugs include Gilead Sciences Inc’s infused antiviral remdesivir and generic steroid dexamethasone, both of which are generally only given once a patient has already been hospitalized.
Monoclonal antibody drugs have so far seen only limited uptake due to the difficulty in their administration.
Coronavirus: Triple antiviral drug shows early promise in treating COVID-19A triple drug combination of antiviral medicines helped relieve symptoms in patients with mild to moderate COVID-19 infection and swiftly reduced the ... Coronavirus
Singapore, pharma firm Merck strike deal to supply COVID-19 antiviral pillPharmaceutical company Merck announced on Wednesday a supply and purchase agreement with Singapore that will ensure it access to its experimental oral ... Coronavirus
Malaysia buys 15,000 courses of antiviral COVID-19 pill from MerckMalaysia has struck a deal with US drugmaker Merck & Co to buy 150,000 courses of its experimental antiviral pill, the health ministry said on ... Coronavirus